Pre-eclampsia is a common condition that affects 2-5% of pregnancies and is associated with significant maternal and perinatal morbidity, and cost to the healthcare system. In those at high risk for pre-eclampsia, interventions such as aspirin intake have been shown to reduce prevalence of disease. However, to implement these interventions, it is essential that high-risk women be identified early in pregnancy. A combined first trimester screening model for pre-eclampsia that includes maternal history, mean arterial pressure, uterine artery Doppler and PlGF has been shown to be the most effective at identifying the population at greatest risk of pre-eclampsia. This article will explore the most appropriate methods of measuring the components of first trimester screening and discuss the use of aspirin for prevention of pre-eclampsia in pregnancy.
Introduction
An appropriate screening test requires that asymptomatic individuals who have a particular disease, or are at a higher risk of developing a condition, are able to be identified by undergoing testing. 1 The principles of screening, as set out by the World Health Organization, recommend that a condition and the associated test meet particular criteria, and new evidence would suggest that pre-eclampsia (PE) can now be counted amongst conditions eligible for population screening (Table 1) . 1 PE affects 2-5% of pregnancies and has a significant health burden on the mother and fetus. 2 Worldwide, PE directly accounts for approximately 50,000 maternal and 500,000 perinatal deaths per year. 2, 3 As a leading cause of iatrogenic preterm birth, the public health burden of PE is also immense. In the USA, a recent study has estimated the cost of PE in the first 12 months at approximately US$ 2.18 billion and this is disproportionally driven by premature deliveries before 32 weeks of gestation with PE. 4 Fortunately, PE does appear to have a latent phase of disease, during which intervention with low-dose aspirin reduces the rates of preterm PE by approximately 60%. 5 Screening tests for PE are non-invasive and can easily be integrated into current antenatal investigations performed at 11-13 weeks of gestation.
As such, guidelines now recommend that women be screened for risk factors in the first trimester, and those identified as high risk receive low-dose aspirin and increased monitoring during pregnancy. 6, 7 There is considerable debate regarding the ideal method of screening, and guidelines traditionally have been consensus based, recommending screening with maternal history alone. 6, 7 However, recent evidence suggests that the addition of biomarkers (uterine artery Doppler, mean arterial pressure, Pregnancy Associated Plasma Protein A, and Placental Growth Factor) to maternal history significantly improves detection rates. [8] [9] [10] [11] As a result, it is likely that with time, guidelines will shift towards a combined screening model for PE. This article will outline the various components of the combined first trimester screening model for PE, how to measure these components, and their efficacy when used as a screening tool. It will also outline the role of aspirin in population groups at high-risk of PE.
resistance circuit that facilitates adequate perfusion of the placenta and fetus. 12 The process of placentation occurs in two waves. In the first 8 weeks of gestation, trophoblasts invade and transform the spiral arteries in the decidua. 13 Between 16 and 18 weeks of gestation, these trophoblasts invade the spiral arteries in the inner third of the myometrium. 13 While the aetiology is unknown and likely multifactorial, the process of placentation does appear to be defective in pregnancies complicated by PE. In PE, trophoblast invasion occurs in 50-70% of spiral arteries and appears to be confined only to the decidual portion of the uterus. 12, 14 The incomplete remodelling of the spiral arteries results in the persistence of a high resistance circuit, which is unable to meet the perfusion requirements of the placenta and fetus. 12 The resulting placental ischaemia triggers the release of anti-angiogenic factors into the maternal circulation. This causes an imbalance of pro-angiogenic and anti-angiogenic factors, resulting in endothelial dysfunction and the subsequent clinical manifestations of PE. 15 Inadequate perfusion of the placenta also results in fetal growth restriction, which is a significant contributor to preterm delivery and the perinatal morbidity associated with PE.
Combined screening
Traditionally, first trimester screening models for PE, such as those endorsed by the National Institute for Health and Care Excellence (NICE) guidelines, have relied on maternal history alone to evaluate risk. If women have one high-risk factor or two moderate risk factors, they are defined as increased risk for PE and are recommended aspirin at a daily dose of 75 mg. 6, 16 Similarly, the American College guidelines only recommend aspirin for those with a history of PE. 7 Unfortunately, these screening protocols have a poor detection rate and miss a large proportion of the population that would have otherwise benefited from intervention. [8] [9] [10] In the Australian setting, the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) guidelines also recommend screening based on history alone. 17 It is important to note that despite the recommendations by SOMANZ guidelines, aspirin prescription for prophylaxis in high-risk population groups is as low as 12-24%. 18 Algorithms have been developed by the Fetal Medicine Foundation (FMF) which combine maternal history with other biomarkers such as mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) on Doppler ultrasound, Pregnancy Associated Plasma Protein A (PAPP-A), and Placental Growth Factor (PlGF). 8 These algorithms are based on equations that estimate the patient-specific risk of developing PE through the addition of biomarkers and modification of the a priori risk, which is derived from Bayes' theorem and previous studies using logistic regression or competing risk models in large populations. 19 In this type of screening, all biomarker results are expressed in multiples of the normal median (MoM) after adjustment for maternal characteristics that influence specific biomarker levels. The risk calculation is performed with the use of software or online calculators (www.fetalmedicine.org).
Studies have shown that this multifactorial approach is associated with a significantly higher detection rate of PE. 8, 9 O'Gorman et al. illustrated that for a 10% false positive rate (FPR), the FMF algorithm has a 100%, 80% and 43% detection rate for PE under 32, <37 and ≥37 weeks respectively. In contrast, the NICE guidelines have a detection rate of 41% and 34% for preterm and term PE respectively. 8 These findings are supported by the SPREE trial, where in 16,747 women screened in the first trimester, the NICE guidelines had a detection rate of 40% for preterm PE. 9 In addition, compliance with the guidelines is low, as only 23% of women at high risk according to NICE used aspirin throughout pregnancy. In contrast, combined screening with the addition of MAP and PAPP-A to maternal history improved screening by 12.3%. 9 It is important to note that the addition of MAP and PAPP-A to a PE prediction model not only significantly improved detection rates, but they are also regularly measured in the first trimester of pregnancy and therefore do not increase the cost of screening. Furthermore, the addition of UtA-PI and PlGF further improved detection rates of preterm PE to 82%. 9 The use of the FMF algorithm for the prediction of early onset PE has also been validated in the Australian population. 20 However, both history and combined screening models perform poorly in the prediction of late onset PE. 9 Identification and prevention of complications in this subgroup remains a challenge.
Components of combined screening
Maternal history Combined screening for PE requires an initial identification of risk, as determined by maternal characteristics and medical 6 The test should be acceptable to the population 7 The natural history of the condition, including development from latent to declared disease, should be adequately understood 8 There should be an agreed policy on whom to treat as patients 9 The cost of case finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole 10 Case finding should be a continuing process and not a "once and for all" project history ( Table 2) . [21] [22] [23] [24] A thorough history should be obtained from women ideally at, or prior to, 11-13 weeks of gestation to determine baseline risk and allow time for intervention and risk factor modification.
Various studies have examined how to use maternal history to predict the risk of PE. While the original NICE guidelines have suggested treating each risk factor independently, recent studies have revealed that a multivariate regression model that combines maternal risk factors results in an improvement in history-based detection rate from 44% to 54%. 6, 21 Mean arterial pressure (MAP) Maternal blood pressure (BP) is routinely used to detect or predict hypertensive disorders of pregnancy. 25 However, to be a valuable tool, BP needs to measured using a validated and reproducible method (Table 3 ) (Figure 1) . 26 Studies have shown that in the first and second trimester of pregnancy, MAP is a better predictor of PE than systolic or diastolic blood pressure. 25 As a result, it is recommended that MAP be used as part of screening algorithms.
Uterine artery doppler (UtA-PI) Increased impedance in the uterine artery Doppler is associated with poorer pregnancy outcomes including PE, fetal growth restriction and preterm birth. 27 In fact, higher resistance in the uterine arteries appears to precede the clinical phase of the disease, and has proven to be a valuable tool in screening for PE, both in the first and second trimesters. Studies have shown that when used in isolation, the UtA-PI has a sensitivity of 48% and specificity of 92% for the prediction of early onset PE. 27 Studies have also shown that the mean UtA-PI as a continuous variable offers a greater predictive value than when the UtA-PI is simply defined categorically as normal or abnormal. 28 Furthermore, the presence or absence of notching does not appear to add value as a screening tool. 29 In the first trimester, the UtA-PI should be assessed between 11 + 0 and 13 + 6 weeks of gestation and is measured as it runs alongside the cervix at the level of the internal os (Table 4 ) (Figure 2) . 30, 31 Measurements performed distal to the cervical os result in a lower pulsatility index (PI) and an inaccurate assessment of PE risk. 32 Trans-abdominal ultrasound should be After resting for 5 minutes, women should be positioned sitting with legs uncrossed.
The arm is supported at the level of the heart.
If the upper arm sits above the level of the right atrium it overestimates BP If the upper arm sits below the right atrium it underestimates BP A regularly calibrated and validated automated device with an appropriate sized cuff is used. Cuff size is determined through measuring mid arm circumference.
Small cuff -<22cm
Normal cuff -22-32cm
Large cuff -33-42cm BP is measured simultaneously in both arms. Two measurements are recorded from each arm and then an average of all four measurements is obtained MAP is calculated using the following equation preferred whenever technically feasible, as trans-vaginal measurements produce higher PI values. 33 
Maternal biochemical markers
Pregnancy associated plasma protein A (PAPP-A) PAPP-A is a glycoprotein produced by both the embryo and placental trophoblasts. It plays an important role in the cleavage of insulin like growth factor, which in turn regulates placental development and fetal growth. 34 Studies have consistently shown that serum PAPP-A concentrations are reduced in pregnancies complicated by PE. 35, 36 In particular, it appears that this association is stronger for preterm PE. 36 As an isolated screening tool, the value of PAPP-A is somewhat modest with only a 20% detection rate (10% FPR). 36 In a combined screening model, the value of PAPP-A remains modest when added to UtA-PI, MAP and PlGF. 9 It is likely that this is a result of the use of two biochemical markers (PAPP-A and PlGF), which overlap and interact in terms of placental function. Thus, a combined model that uses only one of these biochemical markers would suffice. Given PlGF performs slightly better in the combined model when compared to PAPP-A, it is recommended to use PlGF as a first line. However, in clinical situations where PlGF is not tested, PAPP-A is a valuable alternative.
Placental growth factor (PlGF)
PlGF is a vascular endothelial growth factor that is predominately expressed by the placenta. 37 This biomarker plays a key role in angiogenesis of the uteroplacental circulation. 37 In the normal evolution of pregnancy, PlGF concentrations rise and reach a peak at 30 weeks of gestation. 37 However, in pregnancies complicated by PE, PlGF levels are reduced, likely reflecting abnormal placentation. 38 Low PlGF levels appear to precede the clinical phase of disease, and as such, have shown promise as a screening tool. 38 As an isolated screening tool, the detection rates of PlGF measured at 11-13 weeks of gestation are 51% and 32% for PE requiring delivery before and after 34 weeks of gestation respectively, for a 10% false-positive rate. 39 When combined in a multivariate regression model, PlGF significantly improves the detection rate of PE.
19, 39
Measurement of biochemical markers Both PlGF and PAPP-A are measured in serum and plasma samples using enzyme linked immunosorbent assay (ELISA). Various well-validated automated machines (B.R.A.H.M.S Kryptor, Perkin Elmer DELFIA â and Roche Elecsys analytical platforms) have been developed to measure both PlGF and PAPP-A concentrations. These automated analysers can provide results efficiently in approximately 40 min from blood sampling and require regular calibration and quality control.
Managing a positive result
When the combined screening method is used, a risk cut-off of > 1 in 100 would lead to a screen positive rate of about 10%. Within this population, two interventions are required (Figure 3) . First, these women should be prescribed low-dose aspirin (150 mg at night) before 16 weeks of gestation, until 36 weeks of gestation. 5 Second, high-risk women should receive closer monitoring through pregnancy with careful attention to BP and PE symptoms as well as serial growth scans in the third trimester.
The Combined Multimarker Screening and randomised patient treatment with ASpirin for evidence based Identifying the uterine artery PREeclampsia prevention (ASPRE) trial illustrated that in the high-risk population group, low-dose aspirin (150 mg daily) reduces the rates of preterm PE by more than 60%, and PE requiring delivery before 32 weeks by 90%, with no significant increase in maternal and fetal side effects. 5 This has also been demonstrated in the Australian population, where aspirin prophylaxis in women defined as high risk using the FMF algorithm reduced the prevalence of early onset PE by 90%. 40 In this study, 29 high-risk women needed aspirin prophylaxis to prevent one case of early onset PE. 40 Various other randomised controlled trials (RCT) have examined the role of aspirin in the prevention of PE and have shown mixed results. 41, 42 However, a large proportion of these studies were either underpowered, used lower doses of aspirin, or included low-risk population groups in their analysis. 41, 42 In addition, the optimum gestation to commence aspirin to prevent PE is somewhat unclear. While certain studies have shown that aspirin is only beneficial when commenced prior to 16 weeks of gestation, 43 others have disputed this finding, showing that there is still some benefit if aspirin is commenced after 16 weeks of gestational age. 44 Thus, the current consensus remains that aspirin should ideally be commenced prior to 16 weeks of gestation, but it may still be of some benefit even if commenced at later gestational ages. 45 The effect of aspirin also appears dose dependent and the greatest benefit is at doses greater than 100 mg. 46 There is also evidence to support the administration of aspirin at night rather than in the morning. 47 However, additional comparative studies are required to determine the ideal dose and timing of aspirin to prevent PE. Furthermore, the mechanism by which aspirin modulates PE risk is unclear. While some studies have suggested that aspirin exerts its benefit through its antiplatelet properties, others have shown that aspirin increases PlGF production and modulates cytokine levels to within normal limits. 48 Certainly, the mechanism of action of aspirin in PE requires further study as it may provide insight into alternative therapeutic agents.
The importance of audit, compliance, and quality control In order for a screening programme to be effective, it is essential that there is regular quality control and an assurance of interobserver and intra-observer reliability. Sonographers and clinicians require adequate training, accreditation and frequent reaccreditation to ensure quality of results. For MAP and UtA-PI, local and national protocols should encourage individual audit and feedback regarding measurements, and deviation of measurements from expected performance. Studies have in fact shown that for UtA-PI, sonographers that received regular audit and feedback regarding their measurements showed improved performance. 49 The median of all measurements for each operator should be as close as possible to 1.0 MoM and have acceptable spread. In particular, individualised cumulative sum plots have been shown to be a very effective method of providing feedback. 49 
Conclusion
The identification of the population at risk of PE is an important part of antenatal care. While there has been much debate on the methods used to screen for PE, current guidelines fail to identify a large proportion of the cases of preterm PE. Recent evidence suggests that a multifactorial approach which combines maternal history, mean arterial pressure, mean uterine artery PI and PlGF is most effective. Measurement of these variables requires adequate training, credentialing, and regular audit and feedback to ensure quality control. Once women are identified as high-risk strategies such as increased monitoring and low-dose aspirin can be implemented to decrease the incidence of PE and its complications.
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